Exact Sciences Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This Exact Sciences Value Chain Analysis gives you a clear, structured view of how the company creates value through support and primary activities. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Exact Sciences runs on a regulated diagnostics base: CLIA/CAP labs, quality systems, legal compliance, and payer work all have to stay in sync. In 2025, that matters because screening access hinges on reimbursement and clean clinical claims, while oncology products need tight evidence control. Its infrastructure also supports capital use across screening and oncology so lab scale does not outrun compliance.
Human Resource Management
Exact Sciences relies on molecular scientists, lab technologists, bioinformaticians, commercial teams, and medical affairs staff to keep testing accurate and sales aligned. In FY2025, that talent base supports a business that reported about $2.5 billion in annual revenue, so hiring and training stay tied to growth. Strong HR also helps coordinate lab, clinical, and field teams as the product mix expands.
Technology Development
Exact Sciences keeps spending on assay design, bioinformatics, digital ordering, evidence generation, and workflow automation, and that tech stack helps keep Cologuard and Oncotype DX reliable at scale. It also cuts pre-analytic errors, speeds lab throughput, and supports broader clinical evidence, which matters because these tests depend on high accuracy and fast turnaround.
Procurement
Exact Sciences must source collection kits, reagents, lab consumables, automation equipment, and logistics services, so procurement sits at the core of its testing workflow. Tight controls on supplier vetting, pricing, and dual sourcing help cut stockout risk and keep lab throughput steady as volumes rise. For a 2025-scale diagnostics operation, even small delays in reagents or kits can slow testing and raise unit costs. Strong procurement also supports margin discipline by keeping freight, inventory, and rush-order spend in check.
Exact Sciences' 2025 support engine powers scale, compliance, and $2.5B revenue
Exact Sciences' support activities in 2025 center on regulated lab infrastructure, payer compliance, and evidence control, because screening access and oncology claims depend on both. Talent, automation, and bioinformatics keep Cologuard and Oncotype DX accurate at scale. Procurement of kits, reagents, and logistics protects throughput and margin. FY2025 revenue was about $2.5 billion.
| FY2025 | Key support data |
|---|---|
| Revenue | About $2.5 billion |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Exact Sciences runs inbound logistics through a controlled network that receives patient collection kits, pathology materials, and shipped specimens. In FY2025, that intake flow is critical because even small handling gaps can harm sample integrity and delay both colorectal screening and oncology results. Tight chain-of-custody and timing controls help protect test accuracy and patient trust.
Operations
Exact Sciences runs a centralized lab model that processes stool and blood samples, runs molecular assays, and turns raw signals into clinical reports. In 2025, that workflow still sits at the core of Cologuard and Oncotype DX, where speed and accuracy drive demand. Better lab throughput lowers unit costs and shortens turnaround time, which supports scale across a multibillion-dollar screening and oncology franchise.
Outbound Logistics
Exact Sciences sends results electronically to clinicians, health systems, and patients, so doctors can act fast and patients get answers sooner. The same outbound flow also routes billing and documentation, which helps reimbursement teams keep claims moving. Fast, accurate reporting is a real operational edge in cancer testing, where timing can change care decisions.
Marketing and Sales
Exact Sciences' marketing and sales engine uses physician education, oncology and primary-care outreach, payer engagement, and guideline-driven demand to push test adoption. This matters most in Cologuard screening and in precision oncology, where clinician trust and reimbursement shape order volume.
The model is built for high-coverage education, not one-off selling, so each guideline update can lift demand across large patient pools.
Service
Exact Sciences' service layer helps patients and clinicians interpret results, book follow-up care, and solve reimbursement issues, which keeps the cancer-screening funnel moving. In fiscal 2025, that support matters because each saved drop-off can lift completion rates and payer conversion across its high-volume test base. It also supports repeat use by making post-test steps simpler and faster.
Exact Sciences FY2025: Tight Lab Control, Guided Sales, Faster Results
Exact Sciences' primary activities in FY2025 center on a high-control lab and reporting chain: kits and specimens move in tightly tracked, time-sensitive flows, then tests are processed into clinician-ready results. Marketing and sales stay guideline-led, so physician education and payer access drive Cologuard and Oncotype DX demand. Service then helps patients finish follow-up and reimbursement steps.
| Activity | FY2025 focus |
|---|---|
| Operations | Central lab testing |
| Marketing | Physician and payer reach |
| Service | Results and reimbursement support |
Preview Before You Purchase
Exact Sciences Reference Sources
You're previewing the actual Exact Sciences Value Chain Analysis document, not a sample. The content shown below is taken directly from the full report you'll receive after purchase. Unlock the complete, detailed version immediately after checkout – professional, structured, and ready to use.
Frequently Asked Questions
The strongest driver is the company's two-part platform of screening and precision oncology. Exact Sciences turns Cologuard and Oncotype DX into clinical value by linking collection, lab processing, and reimbursement across 2 commercial franchises and 3 major cancer use cases: colorectal, breast, and prostate. That combination makes the operating model more scalable than a single-test business.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.